Frankel Healthcare Private Limited
Frankel Healthcare Private Limited
Mumbai, Maharashtra
TrustSEAL Verified
Call 0804607510873% Response Rate

Antiviral Medicine

Our product range includes a wide range of movfor 200mg molnupiravir capsules.

Movfor 200mg Molnupiravir Capsules

Movfor 200mg Molnupiravir Capsules
  • Movfor 200mg Molnupiravir Capsules
Get Best Quote
Approx. Price: Rs 2,400 / BottleGet Latest Price

Product Details:

Minimum Order Quantity5 Bottle
Packaging Size40 capsules
TreatmentCovid 19 omicron
Prescription/Non prescriptionPrescription
ManufacturerHetero Healthcare

Molnupiravir (development codes MK-4482 and EIDD-2801) is an experimental antiviral drug which is orally active and was developed for the treatment of influenza. It is a prodrug of the synthetic nucleoside derivative N4-hydroxycytidine, and exerts its antiviral action through introduction of copying errors during viral RNA replication.
The drug was developed at Emory University by the university's drug innovation company, Drug Innovation Ventures at Emory (DRIVE). It was then acquired by Miami-based company Ridgeback Biotherapeutics, who later partnered with Merck & Co. to develop the drug further.
Safety controversyIn April 2020, a whistleblower complaint by former Head of US Biomedical Advanced Research and Development Authority (BARDA) Rick Bright revealed concerns over providing funding for the further development of molnupiravir due to similar drugs having mutagenic (DNA damaging) properties.[3] A previous company, Pharmasset, that had investigated the drug's active ingredient had abandoned it. These claims were denied by George Painter, CEO of DRIVE, noting that toxicity studies on molnupiravir had been carried out and data provided to regulators in the US and UK, who permitted safety studies in humans to move forward in the spring of 2020. Also at this time, DRIVE and Ridgeback Biotherapeutics stated they planned future safety studies in animals.
COVID-19In late July 2020 Merck, which had been partnering with Ridgeback Biotherapeutics on developing the drug, announced its intention to move molnupiravir to late stage trials beginning in September 2020. On October 19 2020, Merck began a one year Stage 2/3 trial focused on hospitalized patients.
Yes! I am Interested

Explore More Products

View All Products

Reach Us
Philip (Director)
Frankel Healthcare Private Limited
Shop No G238, Ground Floor, Raghuleela Mega Mall, Off S.V Road, Kandivali West
Mumbai - 400067, Maharashtra, India
Get Directions

Call Us

Send E-mail